Results 31 to 40 of about 2,555,654 (307)

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [PDF]

open access: yes, 2001
The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML). Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA- associated expression of the BCR-ABL peptide KQSSKALQR on class I-negative CIVIL ...
Lill, JR   +14 more
core   +1 more source

Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature

open access: yesJournal of Medical Case Reports, 2018
Background Chronic lymphocytic leukemia and chronic myeloid leukemia are the most common types of adult leukemia. However, it is rare for the same patient to suffer from both.
Khadega A. Abuelgasim   +6 more
doaj   +1 more source

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV [PDF]

open access: yes, 2014
The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in ...
Annette Schreiber   +467 more
core   +2 more sources

Treatment of Ph-positive Chronic Myeloid Leukemia with alpha-Interferon (Roferon-A). The Italian Cooperative Study Group experience.

open access: yes, 1993
This is an interim report of two National studies of human recombinant interferon-alpha 2a (ROFERON-A) in Ph+ chronic myeloid leukemia (CML). The first study (1986-1988) enrolled 322 patients who were randomized to treatment by IFN or by hydroxyurea ...
The Italian Cooperative Study Group on Chronic Myeloid Leukemia   +3 more
core   +1 more source

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]

open access: yes, 2011
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
E K Allan   +7 more
core   +1 more source

Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach [PDF]

open access: yes, 2010
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core   +1 more source

Simultaneous Occurrence of Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia: A Case Report

open access: yesLiječnički vjesnik, 2023
Concurrent development of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) is very rare. We present a case of simultaneous CLL and AML in a patient with no prior exposure to cytotoxic agents or irradiation.
Stjepan Galić, Ozren Jakšić
doaj   +1 more source

Models of chronic myeloid leukemia [PDF]

open access: yesCurrent Oncology Reports, 2001
Models of chronic myeloid leukemia (CML) have proven invaluable for furthering our understanding of the molecular pathophysiology of this disease. Xenotransplantation of primary human CML cells into immunodeficient mice allows investigation into the nature of the most primitive repopulating cells in this leukemia, but the system is limited by ...
openaire   +3 more sources

Stability and Bifurcation of the Immune Model of Chronic Myeloid Leukemia with Time Delay

open access: yesJournal of Harbin University of Science and Technology
In order to investigate the effects of the differentiation delay in chronic myeloid leukemia stem cells on the dynamic behaviors among chronic myeloid leukemia stem cells, chronic myeloid leukemia mature cells and effector T cells, a delayed immune ...
WANG Jingnan, SUN Yue
doaj   +1 more source

Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells

open access: yesHaematologica, 2010
Background Tyrosine kinase inhibitors, such as imatinib, are not considered curative for chronic myeloid leukemia – regardless of the significant reduction of disease burden during treatment – since they do not affect the leukemic stem cells.
Tom Lenaerts   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy